From: Effects of Tocilizumab in COVID-19 patients: a cohort study
Disease severity | n (%) | ||
---|---|---|---|
WHO Ordinal Scale | |||
 8 (deceased) | 0 (0.0) | ||
 7 (invasive mechanical ventilation + organ support) | 17 (28.3) | ||
 6 (invasive mechanical ventilation) | 9 (15.0) | ||
 5 (non-invasive ventilation or high-flow oxygen) | 9 (15.0) | ||
 4 (oxygen by mask or nasal prongs) | 24 (40.0) | ||
 3 (hospitalized without oxygen therapy) | 1 (1.7) | ||
 1–2 (not hospitalized) | 0 (0.0) | ||
Temperature ≥ 38 °C | 28 (46.7) | ||
Heart rate ≥ 100 beats/min | 34 (56.7) | ||
Respiratory rate ≥ 30 breaths/min | 36 (60.0) | ||
Abnormal chest imaging | 59 (98.3) | ||
Vasopressor use | 18 (30.0) | ||
Renal replacement therapy | 4 (6.7) | ||
Use of paralytics | 9 (15.0) | ||
Proned | 5 (8.3) | ||
Room air | 1 (1.7) | ||
Nasal cannula | 18 (30.0) | ||
Venti-mask | 3 (5.0) | ||
Nonrebreather | 7 (11.7) | ||
High-flow nasal cannula | 6 (10.0) | ||
Non-Invasive Positive Pressure Ventilation | 2 (3.3) | ||
Invasive mechanical ventilation | 23 (38.3) | ||
ARDS | |||
 Mild (201 < PaO2/FiO2 ≤ 300) | 13 (21.7) | ||
 Moderate (101 < PaO2/FiO2 ≤ 200) | 21 (35.0) | ||
 Severe (PaO2/FiO2 ≤ 100) | 16 (26.7) | ||
PaO2/FiO2, median (range) | 166 (33–523) | ||
SOFA score, median (range) | 3 (0–11) | ||
ICU care | 45 (75.0) | ||
Laboratory parameters | Median (range) | Reference values | Number of patients with available data |
 White blood cell count, ×109/L | 9 (2.7–29.6) | 4.0–10.5 | 51 |
 Absolute neutrophil count, ×109/L | 6.85 (1.8–26.8) | 2.0–6.0 | 49 |
 Absolute lymphocyte count, ×109/L | 0.8 (0.2–2.6) | 1.1–2.7 | 48 |
 Neutrophil-to-lymphocyte ratio (NLR) | 7.56 (2.25–62) | 0.88-4a | 48 |
 Hemoglobin, g/dL | 12.7 (9–15.9) | 11.1–14.6 | 51 |
 RDW-CV, % | 14 (11.6–18.3) | 11–15 | 51 |
 Platelets, ×109/L | 240 (101–513) | 140–400 | 49 |
 Sodium, mmol/L | 135 (123–148) | 135–145 | 53 |
 CO2, mmol/L | 24 (11–36) | 22–30 | 53 |
 AST, U/L | 70.5 (25–711) | 15–46 | 46 |
 ALT, U/L | 51.5 (6–242) | 9–52 | 46 |
 Total bilirubin | 0.65 (0.2–2.4) | 0.2–1.3 | 48 |
 Creatinine, mg/dL | 0.88 (0.4–4.58) | 0.66–1.25 | 53 |
 Interleukin-6, pg/mL | 133.9 (8.73–2160.69) | none | 26 |
 C-reactive protein, mg/dL | 24.2 (3.2–45) | 0.0–0.9 | 49 |
 Erythrocyte sedimentation rate, mm/hr | 50 (18–102) | 0–10 | 24 |
 Lactate dehydrogenase, U/L | 1333 (477–5089) | 313–618 | 47 |
 Ferritin, ng/mL | 1412.5 (45–29,304) | 30–400 | 46 |
 Procalcitonin, ng/mL | 0.40 (0.027–16.34) | 0–0.08 | 33 |
 D-dimer, mcg/mL | 1.3 (0.4- > 20) | 0–0.49 | 33 |
 Troponin, ng/mL | 0.104 (< 0.012–7.21) | 0–0.034 | 15 |